Stay updated on Nivolumab in Resected Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resected Esophageal Cancer Clinical Trial page.

Latest updates to the Nivolumab in Resected Esophageal Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now shows a new revision label 'Revision: v3.3.2' and removes the previous 'Revision: v3.3.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoChange DetectedAdded new study locations (Seoul, Central Singapore, North Holland, Central Jutland) and site details (e.g., Pittsburgh PA; Aarhus N; Berlin; Amsterdam; Poznan; Songpa-gu), bringing the total locations to 204. Updated follow-up time frame to from randomization to death up to approximately 60 months.SummaryDifference0.9%

- Check23 days agoChange DetectedThe Taiwan site entry was changed from 'Tainan City, Taiwan, 70403' to 'Tainan, Taiwan, 70403'.SummaryDifference0.1%

- Check38 days agoChange DetectedNo significant additions or deletions were detected on the page; the study details, eligibility criteria, and locations appear unchanged.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page now adds a verified date with a status of Active, not recruiting and includes an Unknown status, while removing the prior explicit 'Active, not recruiting' line. This alters how recruitment status is communicated.SummaryDifference0.5%

- Check67 days agoChange DetectedVersion update from v3.0.2 to v3.2.0 indicating a new release; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in Resected Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resected Esophageal Cancer Clinical Trial page.